An Exploratory, Open Label Pharmacokinetic - Pharmacodynamic Study to Compare Subcutaneous Versus Intravenous Administration of ACZ885 in Adult Patients With Established Rheumatoid Arthritis.
Phase of Trial: Phase I/II
Latest Information Update: 21 Jul 2011
At a glance
- Drugs Canakinumab; Canakinumab
- Indications Rheumatoid arthritis
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Novartis
- 31 Aug 2018 Biomarkers information updated
- 25 Aug 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 16 Feb 2009 Planned end date changed from 1 Dec 2008 to 1 May 2009 as reported by ClinicalTrials.gov.